DeviceTalks Podcast Network

The urology specialty faces a critical moment, with 10 urologists ready to retire for every new urologist entering the field. That puts the onus on medical device companies to develop faster, safer and more efficacious ways to break down kidney stones, shrink enlarged prostates and handle other critical treatments. In this week’s episode, we’ll speak with Meghan Scanlon, SVP and president, Urology and Pelvic Health at Boston Scientific about that company’s growing pipeline bolstered by the acquisition of Lumenis.

This episode was sponsored by KNF Neuberger.

We’ll also connect with the leaders of Zenflow – CEO Nick Damiano and President Susan Stimson – about the start-up’s minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH).

Finally, we have all-hands (or most hands) on deck for this episodes Newmarker's Newsmakers. Jim Hammerand, managing editor of Medical Design and Outsourcing, talks about Koya Medical and Hologic. Associate Editor Sean Whooley shares his insights on Varian and Explorer Surgical. Pharma Editor Brian Buntz gives us the latest on the never ending saga of Covid-19 booster approval.

Subscribe on all major podcast applications.

In this first episode of the new IntuitiveTalks Podcast, we’ll start right at the beginning. CEO Gary S. Guthart recalls how a court side basketball conversation led to his introduction to the early form of a surgical robot and convinced him to join. He also shares his expectations for the surging surgical robotics field, including how the company will view emerging competition.

This episode is sponsored by Tegra Medical.

Co-hosts Tom Salemi and Chris Newmarker announce the newest member of the DeviceTalks Podcast family - IntuitiveTalks!

Get it? Attractive? Magnets. Yeh, we’ll, we’re tired from putting this monster podcast episode together but it’s so, so good.

You’ll hear from David Fischel, CEO of Stereotaxis, a 30-plus year old medtech that’s going through a quiet but deliberate reboot. Fischel says he took the company over because Stereotaxis’ magnetic robotic surgery system makes interventional surgery safer, an assertion supported by Daniel Cooper, MD, associate professor at Washington University School of Medicine. Stereotaxis appears to be on the cusp of something big.

Then, Alberto Rodriguez-Navarro, MD, tells us why he sold everything to move from his native Chile to move to Silicon Valley and start Levitra Magnetics. The company is anticipating FDA approval for its own robotic system that could help hospitals overcome staffing shortages during laparoscopic procedures.

We’ll also hear our sponsor Futek explain how its miniaturized sensors are advancing robotic surgery.

Chris Newmarker, executive editor of life sciences, delivers the week’s big news featuring Siemen Healthineers, LumiraDx, Boston Scientific, Abbott and Medtronic. Senior editor Danielle Kirsh updates us on the Theranos trial.

Subscribe to this podcast on all major channels.

This episode of the DeviceTalks Weekly Podcast draws from two realities

First, Russell Powers, worldwide president, shoulder reconstruction, sports medicine, and spine at DePuy Synthes details how the company’s new Inhance Shoulder system will help the company grab market share in the increasingly competitive space.

Later, we meet Dr. Justin Barad, CEO of OssoVR, on his own turf, conducting an interview in OssoVR’s virtual reality training platform. In the interview, Dr. Barad demonstrates why virtual reality training help alleviate the growing demands on surgeons while also improving performance.

Chris Newmarker, executive editor of life sciences, identifies this week’s Newmarker’s Newsmakers including Abbott, Medtronic, and Vicarious Surgical. Senior editor Danielle Kirsh also shares her insights on the ongoing Theranos trial, including damaging testimony from General James Mattis.

Subscribe to this podcast on all major channels!

Zoll Medical’s acquisition of Itamar Medical is just latest sign of the opportunity diagnosing and treating sleep apnea presents to medical device companies, especially following the CPAP machine recall issued by Philips Respironics earlier this summer.

This week, we’ll talk with two of the leaders in this increasingly competitive market.

First, we’ll reconnect with Tim Herbert, CEO of Inspire Medical Systems, to learn how that neurostimulation company is working to serve patients seeking an alternative to CPAP machines.

This is our second visit with Tim Herbert. You can find his earlier interview on DeviceTalks.com.

Then we welcome Michael “Mick” Farrell, CEO of ResMed, the leading provider of CPAP machines. Farrell explains why the apnea market is growing and what this means for the future of ResMed, which has grown into other respiratory businesses.

Chris Newmarker returns! The executive editor of life sciences at MassDevice presents his Newmarker’s Newsmakers including Zoll, Itamar, Medtronic, Medicrea, iRhythm, Zimmer and its new spinout, ZimVie.

We also discuss CMS’s disappointing backtrack on reimbursing innovative technologies.

Danielle Kirsh, senior editor of life sciences, also presents a short report on the trial of Theranos founder Elizabeth Holmes.

Edward Lifesciences’ acquisition of Percutaneous Valve Technologies helped mark the birth of one of medtech’s great game-changers – the development of the transcatheter aortic valve replacement.

In this week’s episode, Stanton Rowe, the former CEO of PVT, will walk us through the early days of TAVR, including the enormous doubt the start-up faced as it developed the technology. He also explained how Edwards came to acquire the start-up, which had strong interest from Medtronic, Boston Scientific, and others.

Rowe, who is now CEO of the NXT Biomedical incubator, also offers some provocative thoughts on the origins of medtech innovation (and explains why he misses medical device conferences.)

Larry Wood, corporate vice president at Edwards Lifesciences, will explain why Edwards opted to pursue PVT rather than continue to develop its own TAVR technology.

He also explains why the clinical trial testing of the valve now known as Sapien was so difficult and how he rewrote the compensation packages for his TAVR sales team to help build confidence in the new technology.

Scan the QR code for more information about our upcoming DeviceTalks Tuesday discussion with Sagentia!

You can subscribe to this podcast on most major podcast players including Amazon, Apple, Google, and Spotify.

This week, DeviceTalks Weekly Podcast examines the single-use endoscope market.

We’ll hear from market leaders Ambu and Boston Scientific in a replay of interviews we conducted in September 2020. Guests include Ambu’s CEO Juan Jose Gonzalez and Stephen Block as well Boston Scientific’s Endoscopy executives Dr. Brian Dunkin, chief medical officer, and Unit President David Pierce.

You’re also invited to participate in a discussion led by TE Connectivity on Tuesday’s DeviceTalks Tuesday.

Chris Newmarker, executive editor of life sciences at MassDevice, presents this week’s top Newmarker’s Newsmakers – Abbott, Boston Scientific, Medtronic, Johnston & Johnson, Auris and Amazon.

Subscribe to this podcast on Amazon, Google, Apple, Spotify and other major apps.

New therapeutic approaches require fresh perspectives, and few perspectives were as fresh as Dr. Steven Mickelsen, the developer of a potentially paradigm shifting cardiac ablation treatment – pulse field ablation.

Dr. Mickelsen, a high school dropout turned musician, fell deep enough in love with electrophysiology to go back to school, obtain a medical degree, and put his inclination to tinker to work in developing a new type of ablation.

In this podcast we’ll walk down the path that led Dr. Mickelsen to create Farapulse, the early pioneer in this form of energy that now belongs to Boston Scientific. Dr. Mickelsen left the company a few years ago but he’s resumed his work helping Acutus Medical bring their technology to the market. He serves as that company’s chief translational science officer.

In our second talk, we connect with Dr. Kenneth Stein, senior vice president and CMO of Boston Scientific’s cardiac rhythm management business.

Dr. Stein allows us to pick up where Farapulse is leaving off, explaining why Boston Scientific bought the company now and what the plans are for the ablation systems, which has CE Mark but still requires FDA approval. Dr. Stein also shares advice for those physicians who may want to join a corporation.

We also bring in Medtronic’s Rebecca Seidel, president of cardiac Ablation Solutions, and Dr. Robert Kowal, vice president of medical affairs and CMO at the cardiac rhythm and heart failure business.

In this excerpt from our recent MedtronicTalks Podcast, Seidel and Dr. Kowal give a quick update on that company’s pulse field ablation technology.

This week’s Newmarker’s Newsmakers is delivered by Senior Editor Danielle Kirsh and Associate Editor Sean Whooley including news from Ultrahuman, Johnson & Johnson, ResMed, Abiomed, and Abbott.

Subscribe to this podcast on Amazon, Apple, Google and Spotify and other leading podcast apps.

Let's get interventional. This week, we talk with leaders from Abbott and Cordis about their plans to advance of medtech's stablest business. Duke Rohlen, executive chair, will explain to co-host Tom Salemi why he led the purchase of Cordis from Cardinal. Meanwhile, Dr. Nick West, CMO and DVP of vascular at Abbott, updates Associated Editor Sean Whooley on the Xience pipeline.

This week's Newmarker's Newsmakers brings the big news from Abbott, Heartflow, Intersect ENT, Intuitive, Medtronic, Philips, and Resmed.

Subscribe to this podcast on all major podcast applications!